Announcements Trials
Browse Landscape

Status

Enrolling by invitation 1

Sponsor Class

OTHER 1

Study Type

Observational 1

Sponsor

Cancer Type

Thoracic 1Endocrine 1CNS 1

Conditions

Carcinoma, Non-Small-Cell Lung 26Lung Neoplasms 25Small Cell Lung Carcinoma 7Breast Neoplasms 5Pulmonary Disease, Chronic Obstructive 4Neoplasms 3Melanoma 3Disease 3Brain Neoplasms 3Triple Negative Breast Neoplasms 2Stomach Neoplasms 2Squamous Cell Carcinoma of Head and Neck 2Prostatic Neoplasms 2Pancreatic Neoplasms 2Ovarian Neoplasms 2Neoplasm Metastasis 2Mesothelioma 2Lymphoma 2Lung Diseases 2Lung Cancer Screening 2Liver Neoplasms 2Kidney Neoplasms 2Hypoxia 2Gastrointestinal Neoplasms 2Esophageal Neoplasms 2Colorectal Neoplasms 2Colonic Neoplasms 2Cardiovascular Diseases 2Arthritis, Rheumatoid 2Anxiety Disorders 2

Interventions

lorlatinib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Enrolling by invitation × Hyperlipidemias × Thoracic × Clear all
NCT06876675 2025-03-14

LORLATINIB-related HYPERLIPIDEMIA in ALK+ Non-Small Cell Lung Cancer

Peking University Third Hospital

Enrolling by invitation
167 enrolled
Thoracic

Carcinoma, Non-Small-Cell Lung, Hyperlipidemias

Data powered by HemOnc (CC BY 4.0) Colophon âš¡